2024
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare